According to public FDA communications, the agency has signaled increased enforcement regarding certain mass-marketed compounded GLP-1 products
Copley, S
Chiang, P.-T., Tsai, L.-K
Serious: Severe bradycardia or heart block Hypotension Heart failure exacerbation Bronchospasm (rare, but possible) Masking of hypoglycemia symptoms in diabetics (important caution) --- Contraindications Severe bradycardia Second or third-degree heart block (without pacemaker) Cardiogenic shock Overt heart failure (uncontrolled) Severe peripheral arterial disease --- Precautions Use cautiously in: Diabetes mellitus (masks hypoglycemia symptoms like tachycardia) Asthma/COPD (though cardioselective, still some risk of bronchospasm) Renal impairment (dose adjustment required) Gradual withdrawal is necessaryabrupt discontinuation can precipitate angina, arrhythmias, or myocardial infarction
take exactly as directed by your provider References Tirzepatide (Compounded) Compounded tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Tesamorelin has a stabilized molecular structure that gives it a longer functional duration and more consistent effects than Sermorelins short 10 to 12 minute half-life
